SCHEDULE: Medtronic, Covidien Boost Orchestra BioMed Stake to 17.8%

Medtronic plc and Covidien Group S.a.r.l. have jointly reported a beneficial ownership of 17.8% in Orchestra BioMed Holdings, Inc. common stock.

Summary

• Medtronic plc and Covidien Group S.a.r.l. jointly beneficially own 10,078,625 shares of Orchestra BioMed Holdings, Inc. Common Stock.
• This ownership represents 17.8% of the total class of securities.
• The percentage is calculated based on 56,464,731 shares of Common Stock issued and outstanding as of November 6, 2025, as reported in Orchestra BioMed's Quarterly Report on Form 10-Q filed November 10, 2025.
• Both reporting persons hold shared voting power and shared dispositive power over all 10,078,625 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a previous disclosure of ownership.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it confirms continued significant institutional ownership by a major industry player, Medtronic, which can be interpreted as a vote of confidence in Orchestra BioMed.

Positives

• Significant institutional ownership by Medtronic plc and its subsidiary Covidien Group S.a.r.l. may signal confidence in Orchestra BioMed's long-term prospects.
• The continued holding of a substantial stake (17.8%) by a major medical technology company like Medtronic suggests a strategic interest in Orchestra BioMed's business or technology.

Negatives

• The filing itself does not contain information that would typically be categorized as 'negatives' regarding the issuer's performance or outlook, as it is solely a beneficial ownership disclosure.

Risks

• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11. Any future deviation from this stated intent could introduce governance-related risks.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Orchestra BioMed Holdings, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Medtronic plc, a global leader in medical technology, maintaining a significant stake in Orchestra BioMed Holdings, Inc. suggests a continued strategic alignment or interest in Orchestra BioMed's specific therapeutic areas or platform technologies. This level of ownership by a major industry player can be viewed positively, indicating potential for future collaboration or validation of Orchestra BioMed's market position within the broader healthcare and medical device sectors.

Stakeholder Impact

• Shareholders: The continued significant ownership by Medtronic and Covidien may provide a sense of stability and institutional backing, potentially influencing investor confidence.
• Management: The presence of a large, strategic investor like Medtronic could influence strategic decisions or future collaborations, though the filing states no intent to change or influence control beyond potential nominations.

Key Dates

Recommendation

The filing indicates a stable, significant institutional ownership by Medtronic, a major player in the medical technology sector. While this is a positive signal of confidence, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The existing strategic relationship and substantial stake suggest a 'hold' position, awaiting further operational updates or financial results from Orchestra BioMed to assess its intrinsic value and growth prospects.

Keywords

Orchestra BioMed Holdings, Medtronic, Covidien Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Medical Technology, Healthcare Investment